NOVARTIS AG-SPONSORED ADR (NVS) Stock News
NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR - Currency: USD
NVS Latest News, Press Relases and Analysis
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans. Let's consider two such corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Mentions: ELV
Only 4% of finance leaders say firms are ‘maturing and scaling’ generative AI use
However, executives across business functions overwhelmingly characterized their companies as at least moving forward with generative AI initiatives.
Sterling Mostly Holds Strength Despite Lower Inflation
After quite an active week of British data, the pound has generally held its strength or gained in various pairs.
Trump's executive order seeks to lower prescription drug prices, including for Medicare - UPI.com
President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort to curb prescription drug prices, including with private insurers.
Analysis: Pharma companies expected to absorb any tariff hit in short term
(Reuters) -U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs would likely be absorbed by drugmakers rather than patients whose payments are often set by health insurance. U.S. health insurers, which pay the bulk of prescription drug costs, act as a buffer between drugmakers and patients, with beneficiaries subject to co-pays and co-insurance based on the prices insurers negotiate with drugmakers. "Patented drugs are already generally set at the price the market will bear, so in that sense manufacturers are not likely to substantially increase the prices of these drugs," said Melissa Barber, postdoctoral fellow at Yale University and an expert on drug pricing.
Blood test to predict tumor recurrence of advanced skin cancer called highly accurate - UPI.com
New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether some stage III melanoma patients are likely to suffer recurrences of cancerous tumors.
J&J projects $400m tariff hit but raises sales outlook
J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv
Here are the top 15 companies for career growth in Singapore, according to LinkedIn
DBS Bank dominates LinkedIn's 2025 Top Companies in Singapore list for the third time in a row, topping the best companies for career growth in the country.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires
We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and […]
Jim Cramer on ServiceNow (NOW): “Is ServiceNow Helped Or Hurt?”
We recently published a list of Jim Cramer Reveals Stocks Benefiting From Tariff Selloff & Discusses These 8 Stocks. In this article, we are going to take a look at where ServiceNow, Inc. (NYSE:NOW) stands against other stocks that Jim Cramer discussed. In his appearance on CNBC’s Squawk on the Street on Thursday, Jim Cramer […]
Is Alphabet Inc. (GOOGL) Among the Best Geothermal Stocks to Buy According to Hedge Funds?
We recently published a list of 10 Best Geothermal Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Alphabet Inc. (NASDAQ:GOOGL) stands against other best geothermal stocks to buy according to hedge funds. Geothermal stocks are companies that use heat from the earth to generate […]
Jim Cramer on UnitedHealth (UNH): Totally Domestic. Totally Independent. That’s What Fund Managers Want
We recently published a list of Jim Cramer Questions Market Logic and Dissects These 7 Key Stocks. In this article, we are going to take a look at where UnitedHealth Group Inc. (NYSE:UNH) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer unpacked the deepening uncertainty […]
Novartis commits $23bn to US manufacturing amid tariff threats
Novartis plans new manufacturing sites and a second R&D hub as it shifts key operations to the US.
Mentions: LLY
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
It's unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is hoping for, some experts said.
Mentions: LLY
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.
Novartis pledges $30.5 billion US investment as pharmaceutical tariffs loom
It joins a growing number of multinational drug companies to announce investments in the US.
Mentions: LLY
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs
Swiss pharmaceutical giant Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities, as drugmakers brace for potential tariffs from the Trump administration.
Mentions: LLY
A $576 Billion Stock-ETF Juggernaut Hit by Extreme Dislocations
(Bloomberg) -- One of the largest exchange-traded funds in the world was left at the widest premium to its underlying holdings since 2008 at the end of Wednesday’s historic session.Most Read from BloombergMidtown Office Building Evacuated on Concerns of Wall CollapseIn Chicago, a Former Steel Mill Looks to Make a Quantum LeapThe Secret Formula for Faster TrainsHelicopter Crashes Into Hudson River With Multiple FatalitiesInside the Quiet, Extravagant Expansion of the Frick CollectionIn another si
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats
Swiss drugmaker Novartis said it plans to spend $23 billion to build and expand 10 facilities in the U.S. as it grapples with Trump's threats of drug tariffs.
Mentions: LLY
Novartis Pledges $23 Billion US Investment as Tariffs Loom
Swiss pharmaceutical giant Novartis AG said it would invest $23 billion in the US over the next five years to ensure all its key drugs for Americans are made in the country, news that comes as President Donald Trump has promised to impose tariffs on global drugmakers.
China's deflationary pressures persist as trade gloom worsens
BEIJING (Reuters) -China's consumer prices fell for the second straight month in March while factory-gate deflation worsened, as an escalating U.S. trade war heightened worries about mounting piles of unsold exports that could drive domestic prices even lower. A nascent pick-up in retail sales and robust expansion in factory activity have been offset by rising unemployment and deflationary pressures, fuelling calls for more stimulus. The consumer price index (CPI) dropped 0.1% last month from a year earlier, National Bureau of Statistics data showed on Thursday.
European Stocks Sink as EU, China Retaliate on Trump’s Tariffs
(Bloomberg) -- European stocks fell to the lowest since January 2024 as the EU and China retaliated with higher tariffs on the US, escalating President Donald Trump’s trade war.The Stoxx Europe 600 Index tumbled 3.5% by the close, with about 97% of its constituents in the red. Health care, energy and real estate stocks fell the most.The European Union approved tariffs on €21 billion ($23.2 billion) of US goods in retaliation for the 25% duties Trump imposed last month on the bloc’s steel and alu
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
European pharma companies warn Trump's tariffs could expedite shift to US
FRANKFURT/LONDON (Reuters) -European pharma companies warned the European Commission president at a meeting on Tuesday that U.S. tariffs would expedite the industry's shift away from Europe and toward the United States. Pharma trade lobby EFPIA, whose members include European pharma giants Bayer, Novartis and Novo Nordisk, said it had called on EU President Ursula von der Leyen to push for "rapid and radical action" to mitigate the "risk of exodus" to the United States.
Why Morgan Stanley Stock Sank Today
Shares of Morgan Stanley (NYSE: MS) fell on Thursday. The wealth management and investment banking giant's stock lost 9.5% as of market close and was down as much as 10.4% earlier in the day. President Donald Trump's dramatic tariff announcement has sent shockwaves through financial markets, hitting investment banks particularly hard.